New Anti-Angiogenesis Target: a Dual-Ligand Receptor

Organization:Boston University, MA, US
I.P. Brief:The present application is directed to the identification of mutations and/or polymorphisms in the Dual Endothelin-l/Angiotensin II Receptor (Dear) that indicate susceptibility to, or show current affliction with, hypertension. Additionally, the present invention discloses methods for the modulation of angiogenesis via the regulation of Dear.
Keywords:Angiogenesis, Cancer, VEGF
Primary Industry:Pharma & Biotech
Specific Market:Cancer Therapy

Full IP Descriptions available on-site.

HIGHLIGHTS
Merck
Corporate Symposium
Harvard OTD
Partner Sponsor

2008 Corporate Presentations
Air Products
Boeing
BP
Cabot
Honda
Kodak
Medtronic
Merck
  • BASF
  • Genzyme
  • Lockheed Martin
  • Sanyo

Event Sponsors
Univalor
AzTE
Jackson Walker

Collocated Events

June 1-5, 2008
Nanotech 2008
Clean Technology 2008
BioNano 2008

Press Sponsor
Business Wire

Commercialization Partner
BusinessWeek

Media Sponsors
(joint with Nanotech 2008) Nature
Science
Red Herring

Supporting Organizations
Boston University
Midwest Research University Network
piribo

 

“A major challenge for both the technology and the financial communities is finding a forum in which all parties can interact and explore possibilities for future innovation. TechConnect was created to fill this void, bringing both sides together under one roof into a setting that ultimately will help significant ground-breaking concepts come to life.”
 
Matthew Laudon, Co-Founder and Director of TechConnect